Relief gets rights from Merck to develop atexakin alfa for peripheral neuropathies treatment

Swiss start-up company Relief Therapeutics has entered an in-licensing agreement from Merck Serono to secure exclusive rights to develop and commercialise atexakin alfa, a human recombinant version of interleukin-6.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news